Bone marrow-independent adventitial macrophage progenitor cells contribute to angiogenesis

Pathological angiogenesis promotes tumor growth, metastasis, and atherosclerotic plaque rupture. Macrophages are key players in these processes. However, whether these macrophages differentiate from bone marrow-derived monocytes or from local vascular wall-resident stem and progenitor cells (VW-SCs) is an unresolved issue of angiogenesis. To answer this question, we analyzed vascular sprouting and alterations in aortic cell populations in mouse aortic ring assays (ARA). ARA culture leads to the generation of large numbers of macrophages, especially within the aortic adventitia. Using immunohistochemical fate-mapping and genetic in vivo-labeling approaches we show that 60% of these macrophages differentiate from bone marrow-independent Ly6c(+)/Sca-1(+) adventitial progenitor cells. Analysis of the NCX-/- mouse model that genetically lacks embryonic circulation and yolk sac perfusion indicates that at least some of those progenitor cells arise yolk sac-independent. Macrophages represent the main source of VEGF in ARA that vice versa promotes the generation of additional macrophages thereby creating a pro-angiogenetic feedforward loop. Additionally, macrophage-derived VEGF activates CD34(+) progenitor cells within the adventitial vasculogenic zone to differentiate into CD31(+) endothelial cells. Consequently, depletion of macrophages and VEGFR2 antagonism drastically reduce vascular sprouting activity in ARA. In summary, we show that angiogenic activation induces differentiation of macrophages from bone marrow-derived as well as from bone marrow-independent VW-SCs. The latter ones are at least partially yolk sac-independent, too. Those VW-SC-derived macrophages critically contribute to angiogenesis, making them an attractive target to interfere with pathological angiogenesis in cancer and atherosclerosis as well as with regenerative angiogenesis in ischemic cardiovascular disorders.

Automated summary

Pathological angiogenesis, which is involved in tumor growth, metastasis, and atherosclerotic plaque rupture, is promoted by macrophages. In this study, it was found that 60% of these macrophages differentiate from bone marrow-independent adventitial progenitor cells. Macrophages are the main source of VEGF in angiogenesis and they also activate progenitor cells to differentiate into endothelial cells. Depletion of macrophages and VEGFR2 antagonism significantly reduce vascular sprouting activity. These findings suggest that targeting VW-SC-derived macrophages may be a potential strategy for interfering with pathological angiogenesis.